Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001280594 | SCV001467804 | pathogenic | Fabry disease | 2020-12-02 | criteria provided, single submitter | clinical testing | Variant summary: GLA c.646dupT (p.Tyr216LeufsX16) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant was absent in 183422 control chromosomes. c.646dupT has been reported in the literature in individuals affected with Fabry Disease (Rodrguez-Mar_2003, Sanofi Genzyme's The Lantern Prjoect). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as pathogenic. |